Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

NCT03594422 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT03594422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03594422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 11, 2018
Completion date
December 31, 2028
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor (gist), solid tumor, adult